Journal
CANCER RESEARCH
Volume 74, Issue 10, Pages 2803-2815Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-13-2732
Keywords
-
Categories
Funding
- Leukaemia Foundation of Australia PhD Research Scholarship
- Cancer Institute
- NSW
- Research Scholar Award
- Royal College of Pathologists of Australasia Research Award
- National Health and Medical Research Council (NHMRC)
- Peter Doherty Biomedical Early Career Fellowship [1071945]
- NHMRC Senior Research Fellowship [511965, 508098]
- Cancer Council NSW [RG 13-02]
Ask authors/readers for more resources
Sphingosine kinase 2 (SK2) may have utility as a prognostic marker in inflammatory diseases such as cancer in which it has been rationalized as a candidate therapeutic target. Here, we show that SK2 has an oncogenic role in acute lymphoblastic leukemia (ALL) by influencing expression of MYC. Genetic ablation of SK2 impaired leukemia development in a mouse model of ALL and pharmacologic inhibition extended survival in mouse xenograft models of human disease. SK2 attenuation in both the settings reduced MYC expression in leukemic cells, with reduced levels of acetylated histone H3 within the MYC gene associated with reduced levels of MYC protein and expression of MYC-regulated genes. Our results demonstrated that SK2 regulates MYC, which has a pivotal role in hematologic malignancies, providing a preclinical proof of concept for this pathway as a broad-based therapeutic target in this setting. Cancer Res; 74(10); 2803-15. (C) 2014 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available